AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 46510 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusion from C.G.L. donors
Number of subjects: 41
Study 46510 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusion therapy
Number of subjects: 41
Study 31876455 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback training
Number of subjects: 41
Study 31876455 — intervention group
Group type: COMPARATOR
Intervention: Video feedback training
Number of subjects: 41
Study 28179488 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced interpersonal counseling (IPC) + mass media (MM) + community mobilization (CM) (intensive)
Number of subjects: 1500
Study 28179488 — intervention group
Group type: COMPARATOR
Intervention: Standard IPC + less-intensive MM and CM (nonintensive)
Number of subjects: 1500
Study 25771840 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 g of n-3 PUFA
Number of subjects: 161
Study 25771840 — intervention group
Group type: COMPARATOR
Intervention: 2 g of placebo (olive oil)
Number of subjects: 161
Study 23534988 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) administered every 3 weeks (q3w)
Number of subjects: 0
Study 23534988 — intervention group
Group type: COMPARATOR
Intervention: sb-paclitaxel administered every 3 weeks (q3w)
Number of subjects: 0
Study 23534988 — intervention group
Group type: COMPARATOR
Intervention: sb-paclitaxel administered weekly
Number of subjects: 0
Study 20666686 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin (500 mg daily, 4 consecutive days per month for 3 consecutive months)
Number of subjects: 100
Study 20666686 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily for 3 consecutive months)
Number of subjects: 100
Study 20666686 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 19187076 — intervention group
Group type: EXPERIMENTAL
Intervention: AVE5026 (5, 10, 20, 40, or 60 mg)
Number of subjects: 690
Study 19187076 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg
Number of subjects: 690
Study 19187076 — intervention group
Group type: EXPERIMENTAL
Intervention: AVE5026 (60 mg)
Number of subjects: 690
Study 17265130 — intervention group
Group type: EXPERIMENTAL
Intervention: PATHS curriculum (intervention group)
Number of subjects: 20
Study 17265130 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 15168134 — intervention group
Group type: EXPERIMENTAL
Intervention: Transprosthetic drainage system (TDS) used in 12 stems (TRIOS)
Number of subjects: 22
Study 15168134 — intervention group
Group type: COMPARATOR
Intervention: Third-generation cementation technique used in 10 stems (CPS)
Number of subjects: 22
Study 10735838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ametop gel
Number of subjects: 120
Study 10735838 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 120
Study 8753732 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser prostatectomy alone
Number of subjects: 32
Study 8753732 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP/532 laser therapy after Nd:YAG treatment
Number of subjects: 32
Study 8753732 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group of 32 patients
Number of subjects: 32
Study 1557967 — intervention group
Group type: EXPERIMENTAL
Intervention: fucithalmic drops twice daily
Number of subjects: 104
Study 1557967 — intervention group
Group type: EXPERIMENTAL
Intervention: chloramphenicol (chlormycetin) ointment twice daily
Number of subjects: 104
Study 1557967 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 104
Study 3924879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpiramide (HR-810)
Number of subjects: 0
Study 3924879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 0
Study 3924879 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 0
Study 3924879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin
Number of subjects: 0
Study 3924879 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 0
Study 3924879 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin-sensitive isolates of Ps. aeruginosa
Number of subjects: 0
Study 3924879 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin-resistant isolates of Ps. aeruginosa
Number of subjects: 0
Study 3924879 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycoside-resistance
Number of subjects: 0
Study 30218626 — intervention group
Group type: EXPERIMENTAL
Intervention: rasagiline 0.5 mg
Number of subjects: 64
Study 30218626 — intervention group
Group type: EXPERIMENTAL
Intervention: rasagiline 1.0 mg
Number of subjects: 64
Study 30218626 — intervention group
Group type: EXPERIMENTAL
Intervention: rasagiline 2.0 mg
Number of subjects: 64
Study 30218626 — intervention group
Group type: EXPERIMENTAL
Intervention: rasagiline 0.5 mg (multiple administration)
Number of subjects: 64
Study 30218626 — intervention group
Group type: EXPERIMENTAL
Intervention: rasagiline 1.0 mg (multiple administration)
Number of subjects: 64
Study 30218626 — intervention group
Group type: EXPERIMENTAL
Intervention: rasagiline 2.0 mg (multiple administration)
Number of subjects: 64
Study 30218626 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study 28419317 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Frequency Lanreotide Autogel (120 mg/21 days)
Number of subjects: 30
Study 28419317 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose Lanreotide Autogel (180 mg/28 days)
Number of subjects: 30
Study 28419317 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HF and HD Lanreotide Autogel
Number of subjects: 30
Study 28419317 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study 26510186 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glucose degradation product (GDP) solution
Number of subjects: 68
Study 26510186 — intervention group
Group type: COMPARATOR
Intervention: Conventional solutions
Number of subjects: 68
Study 23413042 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GCs) treatment
Number of subjects: 21
Study 23413042 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study 21591985 — intervention group
Group type: EXPERIMENTAL
Intervention: NUTRIOSE(®) supplementation (17 g twice daily for 12 weeks)
Number of subjects: 60
Study 19238652 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 20
Study 19238652 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin concentration increase
Number of subjects: 20
Study 17075115 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by 6 months of systemic adjuvant chemotherapy with fluorouracil and folinic acid
Number of subjects: 173
Study 17075115 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone and observation
Number of subjects: 173
Study 14534913 — intervention group
Group type: EXPERIMENTAL
Intervention: carbidopa/levodopa (25/100)
Number of subjects: 25
Study 14534913 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 10326742 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin (500 mg once daily for 5 days)
Number of subjects: 80
Study 10326742 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (500 mg once daily for 3 days)
Number of subjects: 80
Study 10326742 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin
Number of subjects: 80
Study 10326742 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 80
Study 8601548 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex 20 mg/kg/day
Number of subjects: 36
Study 8601548 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 0.2 mg/kg/day
Number of subjects: 36
Study 1752885 — intervention group
Group type: EXPERIMENTAL
Intervention: Early excision (within 72 hours of admission)
Number of subjects: 24
Study 1752885 — intervention group
Group type: COMPARATOR
Intervention: Delayed excision (after 2 weeks post-injury)
Number of subjects: 24
Study 1752885 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 7125726 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 87
Study 7125726 — intervention group
Group type: COMPARATOR
Intervention: Gastric partition
Number of subjects: 87
Study 31674219 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-by-side priming of self-efficacy items with behavioral intention items.
Number of subjects: 134
Study 31674219 — intervention group
Group type: EXPERIMENTAL
Intervention: Definition priming of self-efficacy items with presentation of participant's definition of 'can'.
Number of subjects: 134
Study 31674219 — intervention group
Group type: COMPARATOR
Intervention: Control group completing the same questionnaire without priming.
Number of subjects: 134
Study 31674219 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with strict definitions of 'can' in side-by-side priming.
Number of subjects: 134
Study 31642066 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness Incentive and Navigation (WIN) intervention
Number of subjects: 1259
Study 31642066 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 1259
Study 28605827 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral naltrexone plus a 30-day prescription
Number of subjects: 54
Study 28605827 — intervention group
Group type: EXPERIMENTAL
Intervention: 380 mg intramuscular naltrexone injection
Number of subjects: 54
Study 28605827 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 54
Study 25719534 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal hand hygiene improvement intervention (electronic training video, hand sanitizer, educational posters)
Number of subjects: 324
Study 25719534 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 324
Study 24311467 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss alone (WL)
Number of subjects: 96
Study 24311467 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss with aerobic exercise (WL + AEX)
Number of subjects: 96
Study 24311467 — intervention group
Group type: COMPARATOR
Intervention: Weight loss (combined WL and WL + AEX)
Number of subjects: 96
Study 24311467 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal SAA secretion during WL
Number of subjects: 96
Study 24311467 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluteal SAA secretion
Number of subjects: 96
Study 21895923 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (Group S)
Number of subjects: 75
Study 21895923 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (Group E)
Number of subjects: 75
Study 21895923 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine followed by PCA (Group P)
Number of subjects: 75
Study 21895923 — intervention group
Group type: COMPARATOR
Intervention: DO(2) I < 400 ml/min/m(2)
Number of subjects: 75
Study 21895923 — intervention group
Group type: COMPARATOR
Intervention: DO(2) I > 400 ml/min/m(2)
Number of subjects: 75
Study 19255176 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial infiltration of 1.8 mL of 2 percent lidocaine with 1:100,000 epinephrine plus repeated infiltration of the same anesthetic 30 minutes later
Number of subjects: 40
Study 19255176 — intervention group
Group type: COMPARATOR
Intervention: Initial infiltration of 1.8 mL of 2 percent lidocaine with 1:100,000 epinephrine plus mock repeated infiltration 30 minutes later
Number of subjects: 40
Study 17126039 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine transporters measured using positron emission tomography and [11C]cocaine in ADHD subjects.
Number of subjects: 20
Study 17126039 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine transporters in putamen in ADHD subjects.
Number of subjects: 20
Study 17126039 — intervention group
Group type: COMPARATOR
Intervention: Scores for inattention in ADHD subjects compared to controls.
Number of subjects: 20
Study 16317972 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive dental care provided by nondental primary care providers
Number of subjects: 342
Study 12172084 — intervention group
Group type: EXPERIMENTAL
Intervention: pVL rebounds
Number of subjects: 358
Study 12172084 — intervention group
Group type: EXPERIMENTAL
Intervention: triple therapy
Number of subjects: 358
Study 12172084 — intervention group
Group type: EXPERIMENTAL
Intervention: non-adherence
Number of subjects: 358
Study 12172084 — intervention group
Group type: EXPERIMENTAL
Intervention: isolated pVL rebound
Number of subjects: 358
Study 12172084 — intervention group
Group type: EXPERIMENTAL
Intervention: consecutive pVL rebounds
Number of subjects: 358
Study 10384587 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation methods in Clinical Informatics
Number of subjects: 0
Study 10384587 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10743848 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 48
Study 10743848 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of childhood psychiatric diagnosis
Number of subjects: 48
Study 1884443 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis (Cedilanid 0.02 ng/kg, n = 8)
Number of subjects: 22
Study 1884443 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (2.8 ± 0.5 micrograms/kg/min, n = 8)
Number of subjects: 22
Study 1884443 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 22
Study 6615674 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone-nitrous oxide-enflurane anesthesia with controlled ventilation (n = 10)
Number of subjects: 30
Study 6615674 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone-nitrous oxide-enflurane anesthesia with spontaneous ventilation (n = 10)
Number of subjects: 30
Study 6615674 — intervention group
Group type: COMPARATOR
Intervention: Regional analgesia (n = 10)
Number of subjects: 30
Study 30625052 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid minimally invasive esophagectomy
Number of subjects: 207
Study 30625052 — intervention group
Group type: COMPARATOR
Intervention: Open esophagectomy
Number of subjects: 207
Study 30180291 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise only (G2)
Number of subjects: 114
Study 30180291 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Manipulation of expectations: No psychological effect (G3)
Number of subjects: 114
Study 30180291 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Manipulation of expectations: Psychological effect (G4)
Number of subjects: 114
Study 30180291 — intervention group
Group type: COMPARATOR
Intervention: No Exercise (G1)
Number of subjects: 114
Study 25311746 — intervention group
Group type: EXPERIMENTAL
Intervention: Open popliteal artery aneurysm repair (OPAR)
Number of subjects: 148
Study 25311746 — intervention group
Group type: COMPARATOR
Intervention: Endovascular popliteal artery aneurysm repair (EPAR)
Number of subjects: 148
Study 23298885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal VEGF Trap-Eye (VTE) 2 mg every 4 weeks for 24 weeks
Number of subjects: 177
Study 23298885 — intervention group
Group type: COMPARATOR
Intervention: Sham injections every 4 weeks for 24 weeks
Number of subjects: 177
Study 21860988 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES with medium-frequency current
Number of subjects: 20
Study 21860988 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES with low-frequency current
Number of subjects: 20
Study 18516012 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 300 mg, amoxicillin 1 g, and pantoprazole 20 mg, given twice daily for 7 days (LAP group)
Number of subjects: 76
Study 18516012 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 500 mg twice, tetracycline 500 mg four times, pantoprazole 20 mg twice, bismuth subcitrate 600 mg twice daily for 7 days (MTPB group)
Number of subjects: 76
Study 16870008 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil/5‐MTHF treatment
Number of subjects: 55
Study 16870008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 12771974 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan (1.2 g per day)
Number of subjects: 90
Study 12771974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 10669844 — intervention group
Group type: EXPERIMENTAL
Intervention: Full mite allergen avoidance measures
Number of subjects: 0
Study 10669844 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal regimen)
Number of subjects: 0
Study 8842951 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsally placed sutures
Number of subjects: 26
Study 8842951 — intervention group
Group type: COMPARATOR
Intervention: Palmarly placed sutures
Number of subjects: 26
Study 1379963 — intervention group
Group type: EXPERIMENTAL
Intervention: Orgaran
Number of subjects: 0
Study 1379963 — intervention group
Group type: COMPARATOR
Intervention: Dextran
Number of subjects: 0
Study 1379963 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 6437842 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (5 mg) with acarbose (3 X 100 mg daily)
Number of subjects: 6
Study 6437842 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (5 mg) with placebo
Number of subjects: 6
Study 30796808 — intervention group
Group type: EXPERIMENTAL
Intervention: CNTs (ANAM, CogState, CNS Vital Signs, ImPACT)
Number of subjects: 406
Study 30796808 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 406
Study 29331021 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially microgrooved healing abutments
Number of subjects: 28
Study 29331021 — intervention group
Group type: COMPARATOR
Intervention: Machined healing abutments
Number of subjects: 28
Study 29331021 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 27405061 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-mg group (50-mg intravenous bolus every 6 h during 7 days)
Number of subjects: 122
Study 27405061 — intervention group
Group type: EXPERIMENTAL
Intervention: 300-mg group (100-mg initial bolus followed by continuous infusion of 300 mg daily for 5 days)
Number of subjects: 122
Study 27405061 — intervention group
Group type: COMPARATOR
Intervention: 200-mg group
Number of subjects: 122
Study 27405061 — intervention group
Group type: COMPARATOR
Intervention: 300-mg group
Number of subjects: 122
Study 24476555 — intervention group
Group type: EXPERIMENTAL
Intervention: GET.ON Mood Enhancer
Number of subjects: 128
Study 24476555 — intervention group
Group type: COMPARATOR
Intervention: Online Psychoeducation (OPD)
Number of subjects: 128
Study 24476555 — intervention group
Group type: COMPARATOR
Intervention: GET.ON Mood Enhancer and Online Psychoeducation
Number of subjects: 128
Study 23225445 — intervention group
Group type: EXPERIMENTAL
Intervention: Menatetrenone (MNT) 45 mg daily
Number of subjects: 101
Study 23225445 — intervention group
Group type: COMPARATOR
Intervention: Non-MNT group
Number of subjects: 101
Study 20664964 — intervention group
Group type: EXPERIMENTAL
Intervention: ANXA10 expressing plasmid introduced into MKN-1 cells
Number of subjects: 9
Study 20664964 — intervention group
Group type: COMPARATOR
Intervention: Normal surrounding mucosa
Number of subjects: 9
Study 17420199 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 13778
Study 17420199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13778
Study 16301236 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 30 mg/kg
Number of subjects: 20
Study 16301236 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1.0 microg/kg
Number of subjects: 20
Study 16301236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12049574 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medication
Number of subjects: 1636
Study 12049574 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1636
Study 9864884 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological support offered to the experimental group
Number of subjects: 632
Study 9864884 — intervention group
Group type: COMPARATOR
Intervention: Usual therapeutic procedures followed in the control group
Number of subjects: 632
Study 9164200 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide 500 mg/m2 plus fluorouracil 500 mg/m2 combined with mitoxantrone 10 mg/m2 (CNF)
Number of subjects: 249
Study 9164200 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m2 (CAF)
Number of subjects: 249
Study 9164200 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF
Number of subjects: 249
Study 9164200 — intervention group
Group type: COMPARATOR
Intervention: CNF
Number of subjects: 249
Study 2719894 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoxetine (600 mg daily for 13 days)
Number of subjects: 12
Study 2719894 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (150 mg daily for 13 days)
Number of subjects: 12
Study 2719894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9110 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 0
Study 9110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31213783 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 228
Study 31213783 — intervention group
Group type: COMPARATOR
Intervention: Calcitonin/Placebo
Number of subjects: 228
Study 28211816 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG) infusion
Number of subjects: 0
Study 28211816 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release oral levodopa-carbidopa (LC-oral) treatment
Number of subjects: 0
Study 26408274 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/d
Number of subjects: 11186
Study 26408274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11186
Study 23237136 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg/d
Number of subjects: 27
Study 23237136 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 150 mg/d
Number of subjects: 27